Compare Stocks: CYTK, ROIV, GMAB, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$61.23 -1.8%	$68.90	$56.98 ▼ $88.31	$7.62B	0.41	2.04 million shs	985,624 shs
GMAB Genmab A/S	$43.79 +9.5%	$35.25	$23.62 ▼ $44.34	$27.33B	0.81	4.48 million shs	13.00 million shs
INCY Incyte	$115.71 -1.0%	$121.40	$84.02 ▼ $132.60	$23.45B	0.74	1.74 million shs	1.48 million shs
ROIV Roivant Sciences	$36.49 -2.6%	$36.62	$17.89 ▼ $42.50	$26.36B	1.1	6.40 million shs	8.23 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-1.16%	-6.75%	-24.16%	+11.82%
GMAB Genmab A/S	0.00%	+18.35%	+25.72%	+51.68%	+46.36%
INCY Incyte	0.00%	+2.33%	-7.02%	-1.67%	+31.40%
ROIV Roivant Sciences	0.00%	+8.83%	+1.00%	+4.23%	+103.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$61.23 -1.8%	$68.90	$56.98 ▼ $88.31	$7.62B	0.41	2.04 million shs	985,624 shs
GMAB Genmab A/S	$43.79 +9.5%	$35.25	$23.62 ▼ $44.34	$27.33B	0.81	4.48 million shs	13.00 million shs
INCY Incyte	$115.71 -1.0%	$121.40	$84.02 ▼ $132.60	$23.45B	0.74	1.74 million shs	1.48 million shs
ROIV Roivant Sciences	$36.49 -2.6%	$36.62	$17.89 ▼ $42.50	$26.36B	1.1	6.40 million shs	8.23 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-1.16%	-6.75%	-24.16%	+11.82%
GMAB Genmab A/S	0.00%	+18.35%	+25.72%	+51.68%	+46.36%
INCY Incyte	0.00%	+2.33%	-7.02%	-1.67%	+31.40%
ROIV Roivant Sciences	0.00%	+8.83%	+1.00%	+4.23%	+103.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	72.21% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$43.39	-0.92% Downside
INCY Incyte	2.44	Hold	$129.90	12.27% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	25.07% Upside

Current Analyst Ratings Breakdown

Latest CYTK, ROIV, GMAB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	INCY Incyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B+) ➝ Buy (B)
10/21/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	INCY Incyte	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$138.00 ➝ $140.00
10/20/2026	GMAB Genmab A/S	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$42.00
10/20/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Equal Weight	$119.00
10/19/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$140.00
10/16/2026	INCY Incyte	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$152.00
10/16/2026	CYTK Cytokinetics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$105.00 ➝ $115.00
10/14/2026	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$104.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$88.04M	86.54	N/A	N/A	($5.39) per share	-11.36
GMAB Genmab A/S	$3.72B	7.35	$1.61 per share	27.21	$9.10 per share	4.81
INCY Incyte	$5.14B	4.56	$6.18 per share	18.72	$26.32 per share	4.40
ROIV Roivant Sciences	$7.53M	3,499.41	N/A	N/A	$7.35 per share	4.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	34.48	27.54	2.01	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	14.74	15.33	4.28	27.71%	29.93%	22.88%	10/29/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest CYTK, ROIV, GMAB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3671	N/A	N/A	N/A	$3.74 million	N/A
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.37	N/A	N/A	N/A	$1.20 billion	N/A
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.44	N/A	N/A	N/A	$41.20 million	N/A
10/29/2026	Q3 2026	INCY Incyte	-$3.64	N/A	N/A	N/A	$1.47 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
GMAB Genmab A/S	0.81	2.46	2.44
INCY Incyte	N/A	4.59	4.51
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
GMAB Genmab A/S	7.07%
INCY Incyte	96.97%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
GMAB Genmab A/S	1.54%
INCY Incyte	16.20%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

CYTK, ROIV, GMAB, and INCY Headlines

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares

October 24 at 4:40 AM | americanbankingnews.com

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

October 23 at 2:46 PM | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)

October 23 at 9:45 AM | theglobeandmail.com

Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock

October 23 at 4:52 AM | insidertrades.com

Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

October 23 at 4:47 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 22 at 7:07 PM | marketbeat.com

Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease

October 22 at 7:15 AM | biospace.comB

Roivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinib

October 22 at 1:28 AM | msn.com

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

October 21, 2026 | cnbc.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

October 21, 2026 | seekingalpha.com

Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results

October 21, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up - Here's What Happened

October 21, 2026 | marketbeat.com

Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise

October 21, 2026 | rttnews.com

Roivant Sciences stock surges on positive uveitis trial data

October 21, 2026 | finance.yahoo.com

Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis

October 21, 2026 | finance.yahoo.com

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

October 21, 2026 | seekingalpha.com

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

October 21, 2026 | globenewswire.com

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

October 21, 2026 | globenewswire.com

Roivant Sciences (NASDAQ:ROIV) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Review

October 19, 2026 | americanbankingnews.com

Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run

October 18, 2026 | finance.yahoo.com

Roivant Sciences (ROIV) share price

October 16, 2026 | economictimes.indiatimes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ROIV, GMAB, and INCY Company Descriptions

Cytokinetics NASDAQ:CYTK

$61.23 -1.10 (-1.76%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$61.23 0.00 (0.00%)

As of 10/23/2026 07:39 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Genmab A/S NASDAQ:GMAB

$43.79 +3.79 (+9.48%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$43.80 +0.01 (+0.02%)

As of 10/23/2026 07:57 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Incyte NASDAQ:INCY

$115.71 -1.22 (-1.04%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$115.68 -0.02 (-0.02%)

As of 10/23/2026 07:30 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Roivant Sciences NASDAQ:ROIV

$36.49 -0.96 (-2.56%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$36.62 +0.13 (+0.36%)

As of 10/23/2026 08:00 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ROIV, GMAB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ROIV, GMAB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ROIV, GMAB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ROIV, GMAB, and INCY Company Descriptions

Cytokinetics NASDAQ:CYTK

Genmab A/S NASDAQ:GMAB

Incyte NASDAQ:INCY

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ROIV, GMAB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ROIV, GMAB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ROIV, GMAB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ROIV, GMAB, and INCY Company Descriptions

Cytokinetics NASDAQ:CYTK

Genmab A/S NASDAQ:GMAB

Incyte NASDAQ:INCY

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools